PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations

Authors

X. Le
Y. Yu
Y. Zhao
D. Planchard
Y. Cheng
X. Li
Shirish Gadgeel, Henry Ford HealthFollow
J. Zhang
A. Spira
H. Hayashi
J. Riess
S. Kitazono
N. Leighl
B. Gao
O. Juan-Vidal
A. J. de Langen
J. Mazieres
M. Pérol
Y. Jiang
T. Hu
J. Huang
N. Baio
L. Musib
M. Kowanetz
S. Wang
W. Leung
S. Yea
J. Hsu
J. Wang

Recommended Citation

Le X, Yu Y, Zhao Y, Planchard D, Cheng Y, Li X, Gadgeel S, Zhang J, Spira A, Hayashi H, Riess J, Kitazono S, Leighl N, Gao B, Juan-Vidal O, de Langen AJ, Mazieres J, Pérol M, Jiang Y, Hu T, Huang J, Baio N, Musib L, Kowanetz M, Wang S, Leung W, Yea S, Hsu J, Wang J. PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations. J Thorac Oncol 2024; 19(10):S5-S6-S6.

Document Type

Conference Proceeding

Publication Date

10-1-2024

Publication Title

J Thorac Oncol

Volume

19

Issue

10

First Page

S5-S6

Last Page

S6